The online version of this article (doi:10.1186/1756-8722-7-10) contains supplementary material, which is available to authorized users.
Although Hanabusa H. has received honoraria from Baxter Healthcare, NovoNordisk, Bayer, Pfizer, and KaketsuKen; and has served on advisory boards for Baxter Healthcare (limited to hemophilia care), he has no competing interest related with this case report (Tocilizumab and Chugai Co.). Nagao and Nakazawa declare that they have no competing interests.
AN, SN and HH cared for the patients. AN wrote the manuscript. HH designed the study and helped to draft the manuscript. All authors have read and approved the final manuscript.
Multicentric Castleman disease (MCD) is a lymphoproliferative disorder caused by human herpesvirus 8 (HHV8) infection HIV associated MCD (HIV-MCD) presents with various clinical symptoms. Many HIV-negative MCD patients are often treated with anti-human interleukin-6 (IL6) receptor monoclonal antibodies (tocilizumab), and successful results have been reported. IL-6 plays an important role in the development of both HIV-positive and HIV-negative MCD; however, the efficacy of tocilizumab in HIV-MCD patients is unknown. We herein report the clinical and biologic courses of two HIV-MCD patients treated with tocilizumab. In both cases, a significant and rapid clinical improvement was observed after the first infusion. However, the treatment efficacy was not maintained for a long period, and relapse occurred at 15 and 22 weeks, respectively. Both patients received rituximab and subsequently achieved complete clinical remission. Our report, in addition to data presented in the literature, suggests that tocilizumab could be an initial treatment option in patients with HIV-MCD.
Authors’ original file for figure 113045_2013_371_MOESM1_ESM.jpeg
van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z: Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol. 2010, 8: 486-498. PubMed
Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T: Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005, 106: 2627-2632. 10.1182/blood-2004-12-4602. CrossRefPubMed
Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, Janz S, Scheller J, Rose-John S: HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood. 2012, 119: 5173-5181. 10.1182/blood-2011-09-377705. PubMedCentralCrossRefPubMed
Polizzotto MN, Uldrick TS, Victoria W, Karen A, Wyvill KM, Vickie M, Stefania P, Deirdre O'M, Denise W, Giovanna T, Steinberg SM, Little RF, Robert Y: Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood. 2013, 122: 4189-4198. 10.1182/blood-2013-08-519959. PubMedCentralCrossRefPubMed
Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E: Prospective study of Rituximab in chemotherapy- dependent human immunodeficiency cirus-associated multicentric castleman’s disease: ANRS117 castlemaB trial. J Clin Oncol. 2007, 25: 3350-3356. 10.1200/JCO.2007.10.6732. CrossRefPubMed
Gérard L, Michot JM, Burcheri S, Fieschi C, Longuet P, Delcey V, Meignin V, Agbalika F, Chevret S, Oksenhendler E, Galicier L: Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood. 2012, 119: 2228-2233. 10.1182/blood-2011-08-376012. CrossRefPubMed
Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, Gazzard B, Stebbing J, Kelleher P: Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007, 147: 836-839. 10.7326/0003-4819-147-12-200712180-00003. CrossRefPubMed
- Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II